ClinicalTrials.gg
RecruitingNCT07374029Updated May 5, 2026

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

A Phase 1 interventional study of DC/AML Fusion Vaccine and T-Cell Therapy in Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse, sponsored by David Avigan. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by David Avigan · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.

Planned enrollment
62nd of 120
30 · median 32
Started
2026
with 7 others
Phase 1
37 of 121
6 open now
Primary completion
2027-10
later than 18 of 32 live
Registered
115th of 121
by date

Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 62nd largest by planned enrollment of the 120 interventional ones that give a count, is one of 8 that started in 2026, is one of 37 in phase 1, reaches primary completion later than 18 of the 32 other live ones, and was the 115th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing decitabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid leukemia (AML).

The names of the study drugs involved in this study are:

  • DC/AML fusion vaccine (immune cell vaccine)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)
  • DC/AML Primed T cells (immune cells)
  • Decitabine (a type of chemotherapy drug)
  • Venetoclax (a type of antineoplastic agent)
Read the detailed description

The study is a dose escalation phase I clinical trial to evaluate the feasibility, safety, clinical and immune effects of adoptive T cell therapy with DC/AML Primed T cells in participants with acute myeloid leukemia (AML) treated with decitabine and venetoclax.

The U.S. Food and Drug Administration (FDA) has not approved DC/AML Vaxprimed T cells as a treatment for any disease. This is the first time that DC/AML Primed T cells will be given to humans.

The U.S. Food and Drug Administration (FDA) has not approved DC/AML fusion vaccine as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has approved GM-CSF, decitabine and venetoclax as treatment options for acute myeloid leukemia (AML).

It is expected that about 30 people will take part in this research study

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia, in Relapse

Keywords

  • Acute Myeloid Leukemia (AML)
  • Newly Diagnosed Acute Myeloid Leukemia (AML)
  • Relapsed Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Prior to Tumor Collection

  • Patients must have AML at initial diagnosis for which decitabine/venetoclax is planned as standard of care therapy. This can include patients with IDH or FLT-3 mutations for whom the addition of targeted therapy agents directed at IDH or FLT-3 mutations to the decitabine/venetoclax regimen is preferred per the treating physician.
  • Patients with AML in first relapse after cytotoxic and/or targeted therapy for which decitabine and venetoclax therapy is appropriate standard of care. This can include patients with IDH or FLT-3 mutations for whom the addition of targeted therapy agents directed at IDH or FLT-3 mutations to the decitabine/venetoclax regimen is preferred per the treating physician.
  • performance status ≤ 2 (Appendix A)
  • Participants must have normal organ and marrow function as defined below:

    • total ≤ 2.0 mg/dL
    • /ALT ≤ 3 × institutional
    • creatinine ≤ 2.0 mg/dl
  • The effects of vaccine stimulated T cells on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written document.

Exclusion Criteria Prior to Tumor Collection

  • Patients diagnosed with acute promyelocytic leukemia
  • Patients treated at initial diagnosis who are appropriate for intensive induction therapy.
  • Patients with active systemic disease requiring ongoing systemic therapy are excluded. The following is an exception to this criterion: subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement. Patients with paraneoplastic auto-immune manifestations related to AML are allowed.
  • Patients who have received a prior transplant will be excluded.
  • Because of compromised cellular immunity, patients who have active (HIV), untreated virus (HCV) or evidence of active virus (HBV).
  • Patients must not have active significant cardiac disease characterized by symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
  • Patients must not be pregnant. All premenopausal patients will undergo pregnancy testing. Men will agree to not father a child while on protocol treatment. Men and women will practice effective birth control while receiving protocol treatment.

Inclusion Criteria Prior to Leukapheresis

  • Patients must have obtained a response of PR or better to decitabine and venetoclax as defined in Section 11.
  • Resolution of all HMA/venetoclax related grade III-IV toxicity as per CTC criteria 4.0, other than grade 3 anemia.
  • Laboratories:

    • ≥ 1,000/µL
    • ≥ 50,000/uL
    • Bilirubin ≤ 2.0 mg/dL
    • Creatinine ≤ 2.0 mg/dL
    • AST/ALT ≤ 3.0 x ULN

Exclusion Criteria Prior to Leukapheresis

  • Patients must not have serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Patients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be eligible for leukapheresis
  • Patients with active systemic autoimmune disease requiring ongoing systemic therapy are excluded. The following is an exception to this criterion: subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement. Patients with paraneoplastic auto-immune manifestations related to AML are permitted.
  • Current or prior use of medication within 14 days prior to first T cell infusion. The following are exceptions to this criterion: intranasal, inhaled, topical or local injections (eg. intra-articular injection); steroids as premedication for reactions; systemic corticosteroid at physiologic doses not to exceed 10mg/day of prednisone or equivalent
  • Known human immunodeficiency virus (HIV), untreated hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV).
  • Female subjects who are pregnant, breast-feeding or female patients of who are not employing an effective method of birth control from starting treatment, including dosing interruptions through 90 days after last dose of treatment. Refrain from egg cell donation while receiving vaccination and for at least 90 days after the last dose of treatment.
  • Male subjects who are not employing an effective method of birth control from starting vaccine, including dosing interruptions through 90 days after receipt of the last dose of treatment. Refrain from sperm cell donation while receiving vaccination and for at least 90 days after the last dose of treatment.

Inclusion Criteria Prior to Treatment with DC/AML Primed T cells and DC/AML fusion vaccine

  • Patient completed 4 cycles of decitabine and venetoclax without evidence of disease recurrence or progression
  • Resolution of all chemotherapy related grade III-IV toxicity as per CTC criteria 4.0, other than grade 3 anemia, at the time of initiation of cycle 5, 6, or 7 of decitabine/venetoclax therapy.
  • Laboratories:

    • ANC ≥ 1,000/µL
    • Platelets ≥ 50,000/uL
    • Bilirubin ≤ 2.0 mg/dL
    • Creatinine ≤ 2.0 mg/dL
    • AST/ALT ≤ 3.0 x ULN
  • Generation of adequate yield of T cells to meet dosing requirement
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Adoptive T cell therapy with DC/AML fusion vaccine, decitabine, and venetoclax

    * Baseline visit * Cycles 1 - 2 (28-day cycles): * Days 1 - 5: predetermined dose of Decitabine 1x daily * Days 1 - 21: predetermined dose of Venetoclax 1x daily * Bone marrow biopsy and aspiration at end of Cycle 2 * Leukapheresis * Cycles 3 - 4 (28-day cycles): * Days 1 - 5: predetermined dose of Decitabine 1x daily * Days 1 - 21: predetermined dose of Venetoclax 1x daily

    Drug: Decitabine · Drug: Venetoclax

  • Experimental
    Dose-Escalation

    A standard 3+3 dose escalation design will be used to find the maximum tolerated dose (MTD) of T cells. If less than 1 out of 3 or less than 2 out of 6 participants experience a dose-limiting toxicity (DLT) in a given cohort then escalation will proceed to the next dosing level. If 2 out of 6 participants experience a DLT then the prior dose level will be defined as the MTD. An additional 12 participants will be treated at the MTD. -Cycles 5 - 7 (42-day cycles): * Days 1 - 5: predetermined dose of Decitabine 1x daily * Day 15: predetermined dose of DC/AML Primed T cells 1x daily * Days 1 - 14: predetermined dose of Venetoclax 1x daily * Day 29: predetermined dose of DC/AML fusion vaccine 1x daily * Day 29: predetermined dose of GM-CSF 1x daily Follow up visits monthly for 6 months Longer term follow up every 3 months for 2 years then yearly for 3 years

    Biological: DC/AML Fusion Vaccine · Biological: T-Cell Therapy · Drug: Decitabine · Drug: Venetoclax · Drug: GM-CSF

Interventions

  • BiologicalDC/AML Fusion Vaccine

    Autologous fusion vaccine of dendritic cells and AML cells, via subcutaneous injection (under the skin) per standard of care.

  • BiologicalT-Cell Therapy

    Autologous adoptive T cells, via intravenous (into the vein) infusion, per protocol.

  • A pyrimidine nucleoside analogue, via intravenous infusion, per standard of care.

  • A BCL-2 inhibitor, taken orally per standard of care.

  • DrugGranulocyte-Macrophage Colony-Stimulating FactorStudies of Granulocyte-Macrophage Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous injection, per standard of care.

06

What researchers measure

Primary outcomes

  1. Successful Manufacture and Administration Rate of Vaccine-Educated T Cells

    Successful manufacture and administration rate is defined as the proportion of enrolled participants for whom autologous vaccine-educated T cells are successfully manufactured and administered per protocol.

    Time frame: 28 weeks

  2. Maximum Tolerated Dose (MTD) of Vaccine-Educated T Cells

    The MTD is defined as the highest dose level that one or fewer participants experiences a dose-limiting toxicity (DLT) or one dose level below the maximum administered dose level where two or more participants experience a DLT.

    Time frame: 56 Days

  3. Toxicity Rate of Vaccine-Educated T Cells, Including CRS, Neurotoxicity, and Infections

    Toxicity rate of vaccine-educated T cells is defined as the proportion of participants who experience at least one toxicity, including cytokine release syndrome, neurotoxicity, or infections, out of all participants who receive at least one T-cell infusion.

    Time frame: 5 years

Secondary outcomes

  1. Relapse-Free Survival (RFS) at 1 Year Post Administration of Vaccine Educated T Cells

    RFS based on Kaplan-Meier method is defined as the time from the first T-cell infusion to the first documented disease relapse or death from any cause. Participants without relapse will be censored at the last disease assessment. Relapse is defined as the reappearance of blasts in the blood, or a bone marrow aspirate and biopsy showing \>5% blasts, not attributable to another cause. If there are no circulating blasts, a repeat bone marrow performed \>1 week later documenting more than 5% blasts is necessary to meet criteria for relapse.

    Time frame: 1 year

  2. Relapse-Free Survival (RFS) at 2 Years Post Administration of Vaccine Educated T Cells

    RFS based on Kaplan-Meier method is defined as the time from the first T-cell infusion to the first documented disease relapse or death from any cause. Participants without relapse will be censored at the last disease assessment. Relapse is defined as the reappearance of blasts in the blood, or a bone marrow aspirate and biopsy showing \>5% blasts, not attributable to another cause. If there are no circulating blasts, a repeat bone marrow performed \>1 week later documenting more than 5% blasts is necessary to meet criteria for relapse.

    Time frame: 2 years

  3. MRD Negative Conversion Rate

    MRD negative conversion rate is defined as the proportion of participants who convert from MRD-positive status at baseline to MRD-negative status at a subsequent post-baseline assessment,

    Time frame: MRD samples are collected up to 6 months after the last cell therapy dose.

  4. Median Overall Survival (OS)

    Overall survival (OS), estimated using the Kaplan-Meier method, is defined as the time from registration to death from any cause. Participants without a death event will be censored at the last date they are known to be alive.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 19 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 28, 2026
StartActual
Feb 12, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2030
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374029
Lead sponsor
David Avigan
Responsible party
David Avigan (Sponsor-Investigator, Beth Israel Deaconess Medical Center) — Sponsor-investigator
First posted
Jan 28, 2026
Start date
Feb 12, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
May 5, 2026

Study contacts

David Avigan, MD
Contact
davigan@bidmc.harvard.edu
617-667-9920
Emma Logan, MSN
Contact
eklogan@bidmc.harvard.edu
617-667-9920
David Avigan, MD
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Decitabine · Venetoclax

Start the discussion